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274* Recurrent pancreatitis among cystic ﬁbrosis (CF) patients at
Stockholm CF Centre. Correlations with genotype
F. Karpati1, V.-A. Adermark1, L. Hjelte1. 1Karolinska Institutet, Karolinska Univ
Hosp Huddinge, Stockholm Cystic Fibrosis Centre B 59, Stockholm, Sweden
Pancreatitis occurs mostly in CF patients with normal or reduced pancreatic
function. Previous studies have revealed associations between CFTR mutations as
well as SPINK1 variants and pancreatitis.
Objectives: To determine the frequency of pancreatitis among CF patients attending
Stockholm CF Centre and relate symptoms to laboratory ﬁndings/genotype.
Methods: Patient records were examined regarding pancreatitis, genotype (CFTR
and SPINK1), MR imaging and treatment. Pancreatitis has occurred in 5 of 230
CF patients (4 M). Mean age at diagnosis of pancreatitis was 25.2 (20−35) yrs.
All patients were diagnosed having CF as adults except one (2 yrs of age). Two
patients were pancreatic sufﬁcient and 3 were partially insufﬁcient. Their CFTR
genotypes were: F508del/I506L, R117C/F5508del, S549I/S549I, S945L/T1086I,
F508del/Y109N. One of them also has a SPINK1 variant (homozygocity for
c.101A>G:p.Asn34SER), associated with pancreatitis in non-CF populations. All
patients have been treated with oral mucolytics, pancreatic enzymes and UDCA
during different periods of time and with varying results. However, a lower
frequency of pancreatitis after having received the CF diagnosis and appropriate
treatment was seen in those diagnosed having CF as adults.
Conclusion: In our total CF patient population 2.2% had evidence of recurrent
pancreatitis. The occurrence of SPINK1 variations in the Stockholm material is in
progress. The only patient who so far has been shown to have SPINK1 variation
is actually the youngest one having had pancreatitis. The result of the medications
used is hard to evaluate due to the small number of patients, but in one case the
effect of UDCA was convincing.
275 Evaluation of cystic ﬁbrosis (CF) liver disease and the indication
and effect of ursodeoxycholic acid in a Dutch CF patient cohort
I. Bronsveld1, A. Koop2, M. Sinaasappel3, F. Teding van Berkhout2. 1University
Medical Centre Utrecht, Utrecht, Netherlands; 2University Medical Centre Utrecht,
Pulmonology, Utrecht, Netherlands; 3Erasmus MC Sophia Children’s Hospital,
Gastroenterology, Rotterdam, Netherlands
Aim: To determine indications for starting ursodeoxycholic acid (UDCA) in our
adult cystic ﬁbrosis (CF) population, to evaluate its effect on liver disease and to
relate liver cirrhosis to different CF genotypes.
Methods: The use of UDCA was evaluated retrospectively in 166 adult CF patients
in 2010. Of these patients liver biochemistry tests and ultrasonographic ﬁndings
were collected from medical records before and after the start of UDCA.
Results: One hundred nine of the 166 patients had undergone an ultrasound (US).
Cirrhosis was present in 21.1% (23/109) and 3.7% (4/109) had both cirrhosis and
portal hypertension. In our population 44 patients used UDCA. The most common
indication for the start of UDCA was an increase in one or more liver enzymes (AST,
ALT, AST) in combination with ultrasonographic abnormalities (68.2%; 30/44).
Based on Colombo et al. 56.8% of participants are entitled to UDCA therapy.
There was no relation between increased serum liver enzymes and evidence of
cirrhosis on US before the start of UDCA. The levels of AST, ALT, and GGT were
signiﬁcantly lower after UDCA treatment compared to the levels before starting
UDCA. Of the 23 patients with cirrhosis twenty patients had two severe CFTR
mutations.
Conclusion: In literature there is little evidence for the indication to start UDCA.
In our population UDCA was started mainly based on raised liver enzymes and
ultrasonography abnormalities. Serum liver enzymes are poorly predictive for the
presence of cystic ﬁbrosis related liver disease (CFLD). Therefore ultrasonography
of the liver should be part of the screening for liver disease. A severe genotype
could be a possible risk factor for developing CFLD.
276* Long-term pulmonary outcome in cystic ﬁbrosis (CF) is not
adversely affected in CF associated liver disease treated with
UDCA
M. Kappler1, W. Wesselak1, A.-C. Grimmelt1, J. Glo¨ckner-Pagel1, C. Glasmacher2,
M. Griese1. 1Dr. v. Hauner Children’s Hospital, University of Munich, Germany,
Cystic Fibrosis, Munich, Germany; 2Medicomp Gesellschaft fu¨r Versuchsplanung
und Datenanalyse, Planegg, Germany
Objective: To deﬁne long-term pulmonary outcome in CF patients affected by liver
disease and treated with ursodeoxycholic acid (UDCA).
Methods: In a retrospective analysis, average annual FEV1 values of all consecutive
cases since 1989 of CF patients affected by liver disease with serum liver enzyme
elevation >1.5 upper normal limit >6 months and/or persistent liver enlargement,
all under UDCA treatment, were compared to gender and age matched controls.
Patients: From our cohort of 382 CF patients, 98 cases (56 males) and 98
contemporary controls with a mean age at the beginning of the observation of
14.8 years (range 0.6−36) and 13.3 years (0.5−34) respectively and a mean duration
of observation 7.2 years (1−15) and 7.4 years (1−15) respectively were included as
study population.
Results: Loss of lung function over time was not different between the cases and
controls. Average loss of FEV1 was −1.36/year (±1.86) for the patients with
liver disease and treated with UDCA and −0.94/year (±1.98) for the matched
controls (p = 0.388 in Wilcoxon signed rank test). Similar results were obtained
with the exploratory t-test for paired samples (p = 0.335) and unpaired comparisons
(Wilcoxon-Mann-Whitney p = 0.253).
Conclusion: CF associated liver disease treated with UDCA therapy does not neg-
atively affect long-term pulmonary outcome in CF patients. CF patients affected by
liver disease had a stable lung function over a long observation period, comparable
to that of CF patients not affected by liver disease.
277* Outcome following lung transplantation for patients with cystic
ﬁbrosis related liver disease: a single centre experience
K. Hester1, S. Wiscombe1, G. Parry1, G. Meachery1, D. Anthony1, J. Lordan1,
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Uncertainty remains over the impact of cystic ﬁbrosis related liver disease (CFRLD)
in the context of lung transplantation. We compared outcome following transplan-
tation in patients with and without CFRLD.
A retrospective case note and database review was conducted. Those with signiﬁcant
CFRLD at assessment (deﬁned as persistently deranged liver function tests, liver
ultrasound abnormalities and the use of ursodeoxycholic acid) were identiﬁed. No
subjects had signiﬁcant disturbance of synthetic function.
A total of 238 patients underwent lung transplantation for CF (1989–2010). 62
had signiﬁcant CFRLD at assessment. Overall survival was 82% at 1 year, 62% at
5 years and 51% at 10 years. There was no signiﬁcant difference in survival between
the two groups (p = 0.47). In the CFRLD cohort, mean bilirubin at assessment was
6.37 and 8.3 at 1 year (p = 0.0003: a signiﬁcant rise but values within normal
limits). Mean ALT did not change signiﬁcantly (p = 0.97) and mean ALP fell
from 162 to 146 (p = 0.0004). Of the 62 with CFRLD, 31 had evidence of portal
hypertension on ultrasound and the remainder fatty liver or coarse echogenicity.
24 had an ultrasound scan recorded post transplantation; none showed evidence of
progression. Follow-up revealed 1 death from liver failure, 7.5 years post transplant
and 1 death from bleeding oesophageal varices at six weeks. Two patients with
severe CFRLD underwent lung/liver transplantation, and are both well at 1.5 and
4.5 years post transplantation.
CF patients with pre-existing liver disease at assessment do not have signiﬁcantly
different survival post transplantation and liver disease does not progress in the
majority of patients.
